^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    PPM1B (Protein Phosphatase, Mg2+/Mn2+ Dependent 1B)

    i
    Other names: PPM1B, Protein Phosphatase, Mg2+/Mn2+ Dependent 1B, PP2CB, PPC2BETAX, PP2CBETA, Protein Phosphatase 1B, e34PP2C-Beta, Protein Phosphatase 1B (Formerly 2C), Magnesium-Dependent, Beta Isoform, Protein Phosphatase, Mg2+/Mn2+ Dependent, 1B, Protein Phosphatase 2C, Beta Isoform, Protein Phosphatase 2C-Like Protein, Protein Phosphatase 2C Isoform Beta, PP2C-Beta-X
    3ms
    Decreased PPM1B Expression Drives PRMT5-Mediated Histone Modification in Lung Cancer Progression. (PubMed, Biomolecules)
    Our findings demonstrate that decreased PPM1B expression drives the oncogenic activation of the MP/PRMT5 axis. This mechanism contributes to the aggressive nature of SCC, establishing PPM1B as a promising prognostic marker in lung cancer.
    Journal
    |
    PRMT5 (Protein Arginine Methyltransferase 5) • PPM1B (Protein Phosphatase, Mg2+/Mn2+ Dependent 1B)
    8ms
    TRAF3IP2-AS1 Deficiency Induces Necroptosis to Promote Pancreatic Cancer Liver Metastasis. (PubMed, Cancer Res)
    The elevated production of TGFβ1 created a feedback loop that promoted the transcription of TRAF3IP2-AS1 in tumor cells to balance necroptosis. Overall, these findings identify TRAF3IP2-AS1 as a key regulator of necroptosis and the formation of an immunosuppressive microenvironment in PDAC, providing potential therapeutic targets for treating liver metastasis in patients with pancreatic cancer.
    Journal
    |
    TGFB1 (Transforming Growth Factor Beta 1) • PPM1B (Protein Phosphatase, Mg2+/Mn2+ Dependent 1B) • IGF2BP2 (Insulin Like Growth Factor 2 MRNA Binding Protein 2) • TRAF3IP2-AS1 (TRAF3IP2 Antisense RNA 1)
    9ms
    Focusing on DC cells to optimize the prediction of prognosis and innovative treatment strategies for colon cancer. (PubMed, Sci Rep)
    We developed a novel DCRI that accurately predicts COAD prognosis and immunotherapy response. PPP2CB was identified as a potential therapeutic target, offering new insights for personalized COAD treatment strategies.
    Journal • IO biomarker
    |
    MSI (Microsatellite instability) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • CTSD (Cathepsin D) • DAPK1 (Death Associated Protein Kinase 1) • PPM1B (Protein Phosphatase, Mg2+/Mn2+ Dependent 1B)
    1year
    PPM1B degradation mediated by TRIM25 ubiquitination modulates cell cycle and promotes gastric cancer growth. (PubMed, Sci Rep)
    These findings hold clinical significance by offering opportunities to improve diagnosis and treatment strategies for GC patients. Furthermore, this study provides novel insights into the pathogenesis and progression of GC, expanding our understanding of this disease.
    Journal
    |
    PPM1B (Protein Phosphatase, Mg2+/Mn2+ Dependent 1B)
    1year
    Transcriptomic profiles of single-cell autophagy-related genes (ATGs) in lung diseases. (PubMed, Cell Biol Toxicol)
    The heterogeneity of ATGs expression was dependent on cell subsets, pathologic conditions, and challenges, as well as varied among cellular phenotypes, functions, and behaviors, and the severity of lung diseases. In conclusion, our data might provide new insights into the roles of ATGs in epithelial biology and pulmonary disease pathogenesis, with implications for disease progression and prognosis.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD74 (CD74 Molecule) • BCL2L1 (BCL2-like 1) • CD99 (CD99 Molecule) • CFLAR (CASP8 and FADD-like apoptosis regulator) • PPM1B (Protein Phosphatase, Mg2+/Mn2+ Dependent 1B) • EIF2S1 (Eukaryotic Translation Initiation Factor 2 Subunit Alpha) • MAP2K7 (Mitogen-Activated Protein Kinase Kinase 7) • MAPK3 (Mitogen-Activated Protein Kinase 3) • MAPK8 (Mitogen-activated protein kinase 8) • PPM1A (Protein Phosphatase Mg2+/Mn2+ Dependent 1A) • PPP2CA (Protein Phosphatase 2 Catalytic Subunit Alpha 2) • RHEB (Ras Homolog, MTORC1 Binding)
    1year
    BRISC-Mediated PPM1B-K63 Deubiquitination and Subsequent TGF-β Pathway Activation Promote High-Fat/High-Sucrose Diet-Induced Arterial Stiffness. (PubMed, Circ Res)
    Furthermore, smooth muscle cell-specific Abro1-knockout mice and Brcc3-knockout mice showed attenuated HFHSD-induced arterial stiffness and activation of transforming growth factor-β-Smad (mothers against decapentaplegic homolog) signaling. We elucidated the PPM1B deubiquitination mechanisms and highlighted a potential therapeutic target for metabolic syndrome-related arterial stiffness.
    Journal • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • SMAD4 (SMAD family member 4) • TGFB1 (Transforming Growth Factor Beta 1) • PPM1B (Protein Phosphatase, Mg2+/Mn2+ Dependent 1B)
    1year
    Magnesium-dependent-Protein Phosphatase 1B Regulates the Protein Arginine Methyltransferase 5 Through the Modulation of Myosin Phosphatase. (PubMed, J Biol Chem)
    The results indicate a tumor suppressor role of the PPM1B/MP axis via inhibition of PRMT5, thereby regulating gene expression through H4 arginine dimethylation. Collectively, PPM1B is a tumor suppressor and a possible tumor marker for cervical carcinoma.
    Journal
    |
    PPM1B (Protein Phosphatase, Mg2+/Mn2+ Dependent 1B)
    over1year
    Application of large-scale and multicohort plasma proteomics data to discover novel causal proteins in gastric cancer. (PubMed, Discov Oncol)
    This study identified several plasma proteins as potential biomarkers of GC and provided data support and new insights into the early diagnosis, intervention, and therapeutic targets of GC.
    Journal
    |
    TSC1 (TSC complex subunit 1) • PPM1B (Protein Phosphatase, Mg2+/Mn2+ Dependent 1B) • KDM3A (Lysine Demethylase 3A) • PSCA (Prostate Stem Cell Antigen 2) • THSD1 (Thrombospondin Type 1 Domain Containing 1)
    almost2years
    MLKL promotes hepatocarcinogenesis through inhibition of AMPK-mediated autophagy. (PubMed, Cell Death Differ)
    Consistently, MLKL expression correlates negatively with AMPKα1 phosphorylation in HCC patients. Taken together, our findings highlight MLKL as a novel AMPK gatekeeper that plays key roles in inhibiting autophagy and driving hepatocarcinogenesis, suggesting that the MLKL-AMPKα1 axis is a potential therapeutic target for HCC.
    Journal
    |
    PPM1B (Protein Phosphatase, Mg2+/Mn2+ Dependent 1B) • AMPK (Protein Kinase AMP-Activated Catalytic Subunit Alpha 1) • MLKL (Mixed Lineage Kinase Domain Like Pseudokinase)
    almost2years
    Epithelial-mesenchymal transition induced by tumor cell-intrinsic PD-L1 signaling predicts a poor response to immune checkpoint inhibitors in PD-L1-high lung cancer. (PubMed, Br J Cancer)
    Tumor cell-intrinsic PD-L1 function contributes to NSCLC progression by promoting EMT. EMT may predict an unfavorable outcome after ICI therapy in PD-L1-high NSCLC.
    Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker • Tumor cell
    |
    TGFB1 (Transforming Growth Factor Beta 1) • PPM1B (Protein Phosphatase, Mg2+/Mn2+ Dependent 1B)
    |
    PD-L1 overexpression
    2years
    Modulation of YBX1-mediated PANoptosis inhibition by PPM1B and USP10 confers chemoresistance to oxaliplatin in gastric cancer. (PubMed, Cancer Lett)
    In conclusion, our study reveals the significance of PPM1B-mediated dephosphorylation of YBX1 and USP10-mediated deubiquitination in regulating PANoptosis and sensitivity to oxaliplatin in gastric cancer cells. These findings offer a potential therapeutic strategy for patients with oxaliplatin-resistant gastric cancer.
    Journal
    |
    YBX1 (Y-Box Binding Protein 1) • PPM1B (Protein Phosphatase, Mg2+/Mn2+ Dependent 1B)
    |
    oxaliplatin
    2years
    RBM10 regulates the tumorigenic potential of human cancer cells by modulating PPM1B and YBX1 activities. (PubMed, Exp Cell Res)
    Importantly, these enhanced tumorigenic phenotypes can be reversed by overexpression of PPM1B. Our findings provide the mechanistic bases for functional loss of RBM10 in promoting tumorigenicity, and are potentially useful in the development of combined therapeutic strategies for cancer patients with defective RBM10.
    Journal
    |
    RBM10 (RNA Binding Motif Protein 10) • YBX1 (Y-Box Binding Protein 1) • PPM1B (Protein Phosphatase, Mg2+/Mn2+ Dependent 1B)
    |
    PPM1B overexpression